Medicus Pharma 8-K furnishes Q3 2025 results via Exhibit 99.1

Q: What did MDCX file?

Medicus Pharma Ltd. filed an 8-K announcing it furnished a press release with Q3 2025 financial and operating results and other updates.

Q: Which period does the MDCX update cover?

The press release covers results for the quarter ended September 30, 2025 .

Q: What exhibits are included with MDCX’s 8-K?

Exhibit 99.1 is the press release dated November 14, 2025 ; Exhibit 104 is the cover page Inline XBRL file.

Q: Where are MDCX securities listed and under what tickers?

On the NASDAQ Capital Market as MDCX (common shares) and MDCXW (warrants).

Q: Who signed the MDCX 8-K?

It was signed by Dr. Raza Bokhari , Executive Chairman and Chief Executive Officer.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Medicus Pharma Ltd. filed an 8-K reporting that it furnished a press release covering its financial and operating results for the quarter ended September 30, 2025, along with other corporate updates. The press release is provided as Exhibit 99.1.

The company’s securities listed on the NASDAQ Capital Market include common shares (ticker MDCX) and warrants (ticker MDCXW), with each warrant exercisable for one common share at an exercise price of $4.64 per share.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

11/14/2025 - 05:17 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario	001-42408	98-1778211
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbols	Name of each exchange on which registered
Common shares, no par value	MDCX	NASDAQ Capital Market
Warrants, each exercisable for one common share at an exercise price of $4.64 per share	MDCXW	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On November 14, 2025, the Company issued a press release relating to its financial and operating results for the quarter ending September 30, 2025, and other corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated November 14, 2025.
104		Cover Page Interactive Data File (formatted as Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

MEDICUS PHARMA LTD.

By:	/s/ Raza Bokhari
Name:	Dr. Raza Bokhari
Title:	Executive Chairman and Chief Executive Officer

Dated: November 14, 2025

Source: View Original Filing on SEC EDGAR

FAQ

What did MDCX file?

Medicus Pharma Ltd. filed an 8-K announcing it furnished a press release with Q3 2025 financial and operating results and other updates.

Which period does the MDCX update cover?

The press release covers results for the quarter ended September 30, 2025.

What exhibits are included with MDCX’s 8-K?

Exhibit 99.1 is the press release dated November 14, 2025; Exhibit 104 is the cover page Inline XBRL file.

Where are MDCX securities listed and under what tickers?

On the NASDAQ Capital Market as MDCX (common shares) and MDCXW (warrants).

What are the terms of MDCX warrants noted in the filing?

Each warrant is exercisable for one common share at an exercise price of $4.64 per share.

Which 8-K item did MDCX use for this disclosure?

Item 8.01 (Other Events).

Who signed the MDCX 8-K?

It was signed by Dr. Raza Bokhari, Executive Chairman and Chief Executive Officer.